Evidence map›Paper›PMID 26630001›Full record

ArticlePloS one2015

Silica Vesicle Nanovaccine Formulations Stimulate Long-Term Immune Responses to the Bovine Viral Diarrhoea Virus E2 Protein.

Karishma T Mody, Donna Mahony, Antonino S Cavallaro, Jun Zhang, Bing Zhang, Timothy J Mahony, Chengzhong Yu, Neena Mitter

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Viruses · 2022
    Article
  5. Development of thermostable vaccine adjuvants.Expert review of vaccines · 2021
    Review
  6. Article
  7. Review
  8. Applications of Nanovaccines for Disease Prevention in Cattle.Frontiers in bioengineering and biotechnology · 2020
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Karishma T ModyQueensland Alliance for Agriculture and Food Innovation, The University of Queensland, Brisbane, Australia.
Donna MahonyQueensland Alliance for Agriculture and Food Innovation, The University of Queensland, Brisbane, Australia.
Antonino S CavallaroQueensland Alliance for Agriculture and Food Innovation, The University of Queensland, Brisbane, Australia.
Jun ZhangAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia.
Bing ZhangAnimal Science, Queensland Department of Agriculture and Fisheries, Brisbane, Australia.
Timothy J MahonyQueensland Alliance for Agriculture and Food Innovation, The University of Queensland, Brisbane, Australia.
Chengzhong YuAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia.
Neena MitterQueensland Alliance for Agriculture and Food Innovation, The University of Queensland, Brisbane, Australia.
University of Queensland · AUQueensland Department of Agriculture and Fisheries · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bovine Viral Diarrhoea Virus (BVDV) is one of the most serious pathogen, which causes tremendous economic loss to the cattle industry worldwide, meriting the development of improved subunit vaccines. Structural glycoprotein E2 is reported to be a major immunogenic determinant of BVDV virion. We have developed a novel hollow silica vesicles (SV) based platform to administer BVDV-1 Escherichia coli-expressed optimised E2 (oE2) antigen as a nanovaccine formulation. The SV-140 vesicles (diameter 50 nm, wall thickness 6 nm, perforated by pores of entrance size 16 nm and total pore volume of 0.934 cm3 g(-1)) have proven to be ideal candidates to load oE2 antigen and generate immune response. The current study for the first time demonstrates the ability of freeze-dried (FD) as well as non-FD oE2/SV140 nanovaccine formulation to induce long-term balanced antibody and cell mediated memory responses for at least 6 months with a shortened dosing regimen of two doses in small animal model. The in vivo ability of oE2 (100 μg)/SV-140 (500 μg) and FD oE2 (100 μg)/SV-140 (500 μg) to induce long-term immunity was compared to immunisation with oE2 (100 μg) together with the conventional adjuvant Quil-A from the Quillaja saponira (10 μg) in mice. The oE2/SV-140 as well as the FD oE2/SV-140 nanovaccine generated oE2-specific antibody and cell mediated responses for up to six months post the final second immunisation. Significantly, the cell-mediated responses were consistently high in mice immunised with oE2/SV-140 (1,500 SFU/million cells) at the six-month time point. Histopathology studies showed no morphological changes at the site of injection or in the different organs harvested from the mice immunised with 500 μg SV-140 nanovaccine compared to the unimmunised control. The platform has the potential for developing single dose vaccines without the requirement of cold chain storage for veterinary and human applications.

Indexed as

Adjuvants, ImmunologicAnimalsAntibody FormationBlotting, WesternBovine Virus Diarrhea-Mucosal DiseaseCattleDiarrhea Virus 2, Bovine ViralDrug CarriersEnzyme-Linked Immunosorbent AssayFemaleHumansImmunity, InnateImmunizationImmunoenzyme TechniquesMiceMice, Inbred C57BLAdjuvants, ImmunologicDrug CarriersSilicon DioxideViral Envelope ProteinsViral Vaccines

Identifiers

PMID26630001
PMCPMC4668082
OpenAlexW2185681627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.